The original version of this article contained an error in the funding section. This work was supported by RSF-2017- 00000557 funding from Veneto Region (Italy). Role of the funder/sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The original article has been corrected.

Correction: Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation (British Journal of Cancer, (2023), 128, 2, (266-274), 10.1038/s41416-022-02050-8) / Dieci, M. V.; Carbognin, L.; Miglietta, F.; Canino, F.; Giorgi, C. A.; Cumerlato, E.; Amato, O.; Massa, D.; Griguolo, G.; Genovesi, E.; Garufi, G.; Giannarelli, D.; Tornincasa, A.; Trudu, L.; Michieletto, S.; Saibene, T.; Lo Mele, M.; Fassan, M.; Zarrilli, G.; Piacentini, F.; Bria, E.; Guarneri, V.. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - 128:2(2023), pp. 398-398. [10.1038/s41416-022-02087-9]

Correction: Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation (British Journal of Cancer, (2023), 128, 2, (266-274), 10.1038/s41416-022-02050-8)

Dieci M. V.;Canino F.;Tornincasa A.;Trudu L.;Piacentini F.;Guarneri V.
2023

Abstract

The original version of this article contained an error in the funding section. This work was supported by RSF-2017- 00000557 funding from Veneto Region (Italy). Role of the funder/sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The original article has been corrected.
2023
128
2
398
398
Correction: Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation (British Journal of Cancer, (2023), 128, 2, (266-274), 10.1038/s41416-022-02050-8) / Dieci, M. V.; Carbognin, L.; Miglietta, F.; Canino, F.; Giorgi, C. A.; Cumerlato, E.; Amato, O.; Massa, D.; Griguolo, G.; Genovesi, E.; Garufi, G.; Giannarelli, D.; Tornincasa, A.; Trudu, L.; Michieletto, S.; Saibene, T.; Lo Mele, M.; Fassan, M.; Zarrilli, G.; Piacentini, F.; Bria, E.; Guarneri, V.. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - 128:2(2023), pp. 398-398. [10.1038/s41416-022-02087-9]
Dieci, M. V.; Carbognin, L.; Miglietta, F.; Canino, F.; Giorgi, C. A.; Cumerlato, E.; Amato, O.; Massa, D.; Griguolo, G.; Genovesi, E.; Garufi, G.; Gi...espandi
File in questo prodotto:
File Dimensione Formato  
correction.pdf

Open access

Descrizione: coorection
Tipologia: Altro
Dimensione 245.03 kB
Formato Adobe PDF
245.03 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1312636
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact